4.8 Article

Borrelidin modulates the alternative splicing of VEGF in favour of anti-angiogenic isoforms

Journal

CHEMICAL SCIENCE
Volume 2, Issue 2, Pages 273-278

Publisher

ROYAL SOC CHEMISTRY
DOI: 10.1039/c0sc00297f

Keywords

-

Funding

  1. Wellcome Trust [079663/Z/06/Z]
  2. British Heart Foundation [BS/06/005]
  3. Richard Bright VEGF Research Trust
  4. Welch Foundation [G-1495]
  5. NIDA [DA025800]
  6. German Research Foundation [SP1262/1-1]
  7. NATIONAL INSTITUTE ON DRUG ABUSE [R21DA025800] Funding Source: NIH RePORTER

Ask authors/readers for more resources

The polyketide natural product borrelidin 1 is a potent inhibitor of angiogenesis and spontaneous metastasis. Affinity biopanning of a phage display library of colon tumour cell cDNAs identified the tandem WW domains of spliceosome-associated protein formin binding protein 21 (FBP21) as a novel molecular target of borrelidin, suggesting that borrelidin may act as a modulator of alternative splicing. In support of this idea, 1, and its more selective analog 2, bound to purified recombinant WW domains of FBP21. They also altered the ratio of vascular endothelial growth factor (VEGF) isoforms in retinal pigmented endothelial (RPE) cells in favour of anti-angiogenic isoforms. Transfection of RPE cells with FBP21 altered the ratio in favour of pro-angiogenic VEGF isoforms, an effect inhibited by 2. These data implicate FBP21 in the regulation of alternative splicing and suggest the potential of borrelidin analogs as tools to deconvolute key steps of spliceosome function.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available